This clinical study is a Phase 1 randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial of MORAb-022 in healthy patients and patients with rheumatoid arthritis.

This trial is currently recruiting healthy patients to evaluate the safety and tolerability of single escalating intravenous (IV) doses of MORAb-022 in healthy patients and patients with rheumatoid arthritis (RA). This Phase 1 trial is currently being conducted in Europe.

For more information about MORAb-022, please click here (ClinicalTrials.gov Identifier: NCT01357759).
 

The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.